Evidence map›Paper›PMID 41835166›Full record

ArticleRevista panamericana de salud publica = Pan American journal of public health2026

[Substandard and falsified medical products: 25 years of successful network collaboration among regulatory authorities in the AmericasProdutos médicos de qualidade inferior e falsificados: 25 anos de colaboração bem-sucedida em rede entre autoridades reguladoras da Região das Américas].

Juanita Vahos Zambrano, Gabriela Carrasco, Robin Rojas-Cortés, María José Alfonso, Romina Viñas, Maximiliano Derecho, Miriam Munguía, Danini Marin, José Luis Castro, María Luz Pombo-Castro

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Revista panamericana de salud publica = Pan American journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juanita Vahos ZambranoDepartamento de Farmacia Universidad Nacional de Colombia Bogotá Colombia Departamento de Farmacia, Universidad Nacional de Colombia, Bogotá, Colombia.
Gabriela CarrascoConsultora independiente San Martín de los Andes Argentina Consultora independiente, San Martín de los Andes, Argentina.
Robin Rojas-CortésOrganización Panamericana de la Salud Washington, D. C. Estados Unidos de América Organización Panamericana de la Salud, Washington, D. C., Estados Unidos de América.
María José AlfonsoCentre for Medicine Use and Safety Faculty of Pharmacy and Pharmaceutical Sciences Monash University Parkville Australia Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.
Romina ViñasAdministración Nacional de Medicamentos Alimentos y Tecnología Médica Ciudad Autónoma de Buenos Aires Argentina Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, Ciudad Autónoma de Buenos Aires, Argentina.
Maximiliano DerechoConsultor independiente Ciudad Autónoma de Buenos Aires Argentina Consultor independiente, Ciudad Autónoma de Buenos Aires, Argentina.
Miriam MunguíaComisión Federal para la Protección contra Riesgos Sanitarios CDMX México Comisión Federal para la Protección contra Riesgos Sanitarios, CDMX, México.
Danini MarinConsultora independiente Belmopán Belice Consultora independiente, Belmopán, Belice.
José Luis CastroConsultor independiente Ciudad Autónoma de Buenos Aires Argentina Consultor independiente, Ciudad Autónoma de Buenos Aires, Argentina.
María Luz Pombo-CastroOrganización Panamericana de la Salud Washington, D. C. Estados Unidos de América Organización Panamericana de la Salud, Washington, D. C., Estados Unidos de América.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To present the background, results, contributions, challenges, future prospects of the Regional Network of Focal Points for Prevention, Detection, and Response to Substandard and Falsified Medical Products (SF Network) in the Americas during the two decades of its existence. Method: A documentary review was conducted to identify the background, results, and future prospects of the SF Network. The time horizon considered was 1999 -2025. The data are presented in narrative form. Results: At present, 28 countries in the Region of the Americas have active participation in the initiative. This has made it possible to: exchange information on nearly 650 incidents over the past 10 years; publish 12 technical documents on this subject; and convene 14 national meetings and workshops in the Region. The three key achievements of the initiative are collaborative work, the strengthening of market surveillance and control capacities among members, and the sustainability strategy. Conclusions: The achievements, experiences, and actions of the SF Network represent a success story that demonstrates the value and necessity of using models that facilitate exchange and collaboration between countries. The future of the SF Network should focus on new forms of member participation that strengthen the development of solutions and strategies, in relation to both known issues and emerging regional and global challenges.

Indexed as

AmericasCounterfeit drugshealth surveillance of productsproduct surveillance, postmarketingsubstandard drugs

Identifiers

PMID41835166
PMCPMC12983921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.